Sandoz UK statement on Coronavirus (COVID-19) and supply chain
Mar 20, 2020
We at Sandoz UK continue to closely monitor the coronavirus situation, with our priorities being the supply of our medicines to NHS patients and the health and safety of our associates. We will continue to ensure supply of our medicines to patients in the UK and we do not anticipate disruption at this time.
Sandoz has already issued a statement in recent weeks stating we are committed to keeping prices stable for a basket of essential medicines that may help in the treatment of coronavirus cases, specifically antivirals to reduce the impact of coronavirus and antibiotics to combat pneumonia. This statement can be found here
Sandoz UK has put the following measures in place:
As part of our business continuity plans and in line with requests from the Department of Health and Social Care, we are maintaining increased inventories across our medicines portfolio for both Sandoz and Novartis.
Also in line with DHSC requests, and to help minimise disruption to patients in the UK, we will;
Keep fulfilling orders and supplying products to the NHS in the normal way.
Monitor orders carefully and consider demand management plans in the event of unusual ordering patterns.
Continue to work together with the DHSC to keep them informed of our supply chain risk assessments, which currently have adequate supply to meet usual levels of demand.
We have issued guidance on how our associates can protect themselves against coronavirus infection including updated travel advice in line with warning levels provided by the UK Government.
We have provided guidance to our associates on how to ensure continuity in our engagement with our customers without compromising any local coronavirus containment policies. This is particularly the case with respect to healthcare professionals, with our field based associates now working exclusively on a virtual basis, except in those circumstances where both parties believe it is beneficial and safe to conduct a face-to-face meeting.
Sandoz UK remains responsive to any developments regarding coronavirus and will take all necessary steps to protect its associates and patients as the situation evolves.
Sandoz is the generic and biosimilar division of the Novartis group. If you have any further questions or feedback please contact the Novartis UK press office at [email protected]